Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Anti-TNFa therapy may increase vitiligo risk

18 Dec 2017

Treatment with antitumor necrosis factor-alpha (anti-TNFa) appears to carry an increased risk of developing vitiligo but not alopecia areata (AA), a study has found.

Drawing data from the Korean National Health Insurance Claims database, researchers examined 11,442 patients with ankylosing spondylitis, Crohn’s disease or ulcerative colitis who received anti-TNFa therapy vs an identical number of matched patients without treatment exposure.

Vitiligo had an incidence rate of 5.9/10,000 person-years in the anti-TNFa group vs 2.5/10,000 person-years in the unexposed group. In multivariable Cox proportional hazards models, there was a significant association between anti-TNFa therapy and the risk of vitiligo (hazard ratio 1.99; 95 percent CI, 1.06 to 3.75). Subgroup analyses revealed that vitiligo risk was greater in younger patients and those treated with etanercept.

On the other hand, the risk of AA was not significantly different between the anti-TNFa and unexposed groups.

“Our results provide insight on the role of cytokine imbalance in the pathogenesis of vitiligo,” researchers said.

The immunogenesis of vitiligo, an acquired immune disorder of the skin characterized by the presence of white depigmented macules, is not completely understood. However, some researchers hypothesized that TNFa plays an important role in vitiligo as it is essential in regulating apoptosis in many cell types including T lymphocytes, and an abnormal expression of TNFa has been observed in patients with the skin condition. [Med Hypotheses 2009;72:546-7]

TNFa suppression is said to be an effective treatment of vitiligo, with topical tacrolimus ointment showing promise as an effective alternative therapy for vitiligo, particularly when the disease involves the head and neck. In a previous study, patients who received treatment showed reduced post-treatment expression of some cytokines, including TNFa, in the depigmented and adjacent uninvolved skin. [J Am Acad Dermatol 2004;51:52–61]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.